Related Experiment Video

Updated: Jul 12, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow

Mustafa Caliskan1, Dogan Erdogan, Hakan Gullu

  • 1Baskent University, Konya Teaching and Medical Research Center, Cardiology Department, Konya, Turkey. caliskandr@yahoo.com

Clinical Cardiology
|September 7, 2007
PubMed

Insights

Atorvastatin therapy improved coronary microvascular function in patients with slow coronary flow. This study shows short-term statin use enhances coronary flow reserve, suggesting a benefit for this patient group.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Statins are known to improve endothelial function in coronary artery disease.
  • Limited data exists on statins' effects on myocardial microcirculation, particularly in slow coronary flow (SCF).
  • Microvascular abnormalities and endothelial dysfunction are implicated in SCF, but statin effects remain unstudied.

Purpose of the Study:

  • To prospectively investigate the impact of atorvastatin on coronary microvascular function in SCF patients.
  • To assess changes in coronary flow reserve (CFR) using transthoracic Doppler echocardiography (TTDE).

Main Methods:

  • An open clinical trial involving 20 SCF patients.
  • Assessment of CFR via TTDE at baseline and after 8 weeks of atorvastatin.
  • Measurement of coronary flow using TIMI frame count (TFC) and diastolic peak flow velocities.

Main Results:

  • Coronary flow reserve (CFR) significantly increased after 8 weeks of atorvastatin (p < 0.001).
  • The improvement in CFR was not directly correlated with the lipid-lowering effect of atorvastatin.
  • No significant changes in hemodynamic parameters were observed during the study.

Conclusions:

  • Short-term atorvastatin therapy enhances coronary flow reserve in patients with slow coronary flow.
  • These findings suggest a potential therapeutic benefit of statins for improving coronary microvascular function in SCF.
Abstract

More Related Videos

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice05:07

Dynamic Assessments of Coronary Flow Reserve after Myocardial Ischemia Reperfusion in Mice

Published on: August 25, 2023

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...